News Rob Bent News Rob Bent

7 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma

7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.

Read More